Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA

Summary

Eligible,healthy infants who have finished the 3-dose-schedule of sIPV+DTaP combined vaccination clinical trial (NCT04053010) will be recruited and divided into 4 groups, and will receive vaccination at the age of 18-month-old as follows: 1. Group 1: sIPV + DTaP + HepA, 2. Group 2: sIPV only, 3. Group 3: DTaP only, 4. Group 4: HepA only. The immunogenicity and safety of the 4 groups will be compared and analyzed before and 30-40 days after vaccination.

Timeline

Start

2020-11-11

Primary completion

2021-08

Completion

2021-12

Publications

• Liu X, Han S, Wang H, Sun L, Zhang C, Chen X, Wang R, Chang S, Shi X, Chen H, Wang Y, Zhang D, Guo Y, Zhang S, Hu W. Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled non-inferiority trial in China. Vaccine. 2025 Nov 20;67:127891. doi: 10.1016/j.vaccine.2025.127891. Epub 2025 Oct 27.

Drugs

Indications

No indication recorded.